Infosys Limited vs Health Care Select Sector SPDR Fund — how do they compare? Infosys Limited trades at $12.6 (market cap $50.55B), while Health Care Select Sector SPDR Fund trades at $168.42. The key difference: Infosys Limited pays a 4.16% dividend while Health Care Select Sector SPDR Fund pays none, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Infosys Limited nearer its low. Which is the better fit depends on your goals.
| INFY | XLV | |
|---|---|---|
Market Cap | $50.55B | — |
Sector | Technology | — |
52-Week High | $20.22 | $168.44 |
52-Week Low | $10.49 | $131.16 |
Enterprise Value | $48.30B | — |
Dividend Yield | 4.16% | — |
Signals from Pluang's Aura AI — not financial advice
INFY trades at $12.215, down 2.75% today, with mixed technical signals showing a bullish moving average trend but bearish oscillators including RSI above 76. Fundamentally, the company maintains strong profitability with 16.37% net margins and 32.12% ROE, though Q2 2026 earnings missed expectations. Recent news highlights strategic AI collaborations with Metsä Group and Sentara Healthcare while Q1 2027 results showed revenue challenges but margin resilience.
The outlook remains cautious with analyst consensus at Hold (55%) and $11.05 price target below current levels. Key opportunities include growing AI revenue streams and strong cash flow generation, while risks involve revenue growth volatility and competitive IT services market pressures. The stock faces near-term headwinds from lowered growth guidance but maintains solid fundamentals.
XLV, the Health Care Select Sector SPDR ETF, trades at $167.93, down 0.3% on the day, with a bullish technical signal driven by moving averages. The ETF offers broad healthcare exposure with a low expense ratio of 0.08% and a trailing dividend yield of 1.6%, positioning it as a cost-effective defensive play amid market volatility. Recent news highlights strong sector inflows and defensive demand, with earnings from key holdings like UnitedHealth showing resilience despite Medicaid pressures.
The outlook for XLV is positive, supported by its defensive characteristics and institutional interest, though risks include regulatory pressures and sector-specific volatility. Investors may find value in its diversification and steady performance, but should monitor healthcare policy developments and earnings trends for sustained growth.
Trailing returns across standard periods
Latest headlines on both assets
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →